Cutler Group LP Incyte Corp Call Options Transaction History

Cutler Group LP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$52.16 - $64.19 $151,264 - $186,151	2,900 New	2,900 $16,000
Q1 2022 Apr 14, 2022	SELL	$66.02 - $79.71 $732,822 - $884,780	-11,100 Reduced 99.11%	100 $1,000
Q4 2021 Jan 18, 2022	BUY	$63.34 - $74.11 $424,378 - $496,537	6,700 Added 148.89%	11,200 $53,000
Q3 2021 Oct 26, 2021	BUY	$68.67 - $84.02 $309,015 - $378,090	4,500 New	4,500 $2,000
Q1 2021 Apr 26, 2021	SELL	$76.02 - $100.5 $38,010 - $50,250	-500 Closed	0 $0
Q1 2020 May 07, 2020	SELL	$63.18 - $85.97 $315,900 - $429,850	-5,000 Reduced 90.91%	500 $2,000
Q3 2019 Oct 28, 2019	SELL	$72.82 - $86.52 $764,609 - $908,460	-10,500 Reduced 65.63%	5,500 $5,000
Q2 2019 Aug 09, 2019	BUY	$73.52 - $88.7 $764,608 - $922,480	10,400 Added 185.71%	16,000 $38,000
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $1.44 Million - $1.99 Million	-22,600 Reduced 80.14%	5,600 $32,000
Q4 2018 Feb 05, 2019	BUY	$58.5 - $69.94 $748,800 - $895,232	12,800 Added 83.12%	28,200 $47,000
Q3 2018 Nov 07, 2018	SELL	$61.75 - $74.23 $308,750 - $371,150	-5,000 Reduced 24.51%	15,400 $23,000
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $2.43 Million - $3.35 Million	-39,900 Reduced 66.17%	20,400 $39,000
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $2.05 Million - $2.49 Million	24,700 Added 69.38%	60,300 $238,000
Q4 2017 Jan 17, 2018	SELL	$93.56 - $116.6 $4 Million - $4.99 Million	-42,800 Reduced 54.59%	35,600 $255,000
Q3 2017 Oct 17, 2017	BUY	$109.15 - $138.27 $8.56 Million - $10.8 Million	78,400	78,400 $619,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.